FINAL RESULTS OF A RANDOMIZED PHASE II STUDY OF PERIFOSINE IN COMBINATION WITH CAPECITABINE (P-CAP) VS. PLACEBO PLUS CAPECITABINE (CAP) IN PATIENTS WITH.

Slides:

Advertisements

Similar presentations

FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev

Advertisements

Novel AKT Inhibitor Afuresertib in Combination with Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity.

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Robertson JFR et al. J Clin Oncol 2009;27(27):

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.

A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas Study Update – November 2008 Dejka Araujo, MD MD Anderson Cancer Center, Houston,

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Results of the X-PECT Study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) vs. placebo plus capecitabine.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results.

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Phase I/II Trial of Docetaxel plus Oxaliplatin and 5-Fluorouracil (D-FOX) in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer Jaffer.

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC Reviewer: Dr. Scott Berry Date posted: October 2011.

Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,

Kang Y et al. Proc ASCO 2010;Abstract LBA4007.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.

Phase III Study of First-Line XELOX Plus Bevacizumab (BEV) for 6 Cycles Followed by XELOX Plus BEV or Single Agent (s/a) BEV as Maintenance Therapy in.

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.

Phase I/II study of oral fluoropyrimidine S-1 plus oral Leucovorin as first-line treatment for metastatic colorectal cancer T. Yoshino 1, W. Koizumi 2,

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.

CCO Independent Conference Coverage

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Alessandra Gennari, MD PhD

Gajria D et al. Proc SABCS 2010;Abstract P

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

University of Southern California, Norris Comprehensive Cancer Center

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Mateos MV et al. Proc ASH 2013;Abstract 403.

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

Barrios C et al. SABCS 2009;Abstract 46.

Krop I et al. SABCS 2009;Abstract 5090.

Baselga J et al. SABCS 2009;Abstract 45.

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The.

R Hermann6, P Sportelli7, L Gardner7 and J Bendell8

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Presentation transcript:

FINAL RESULTS OF A RANDOMIZED PHASE II STUDY OF PERIFOSINE IN COMBINATION WITH CAPECITABINE (P-CAP) VS. PLACEBO PLUS CAPECITABINE (CAP) IN PATIENTS WITH SECOND OR THIRD LINE METASTATIC COLORECTAL CANCER (mCRC) Donald Richards 1, John Nemunaitis 2, Sasha Vukelja 1, Christopher Hagenstad 3, Luis Campos 4, Jeffrey Letzer 5, Robert Hermann 6, Peter Sportelli 7, Lesa Gardner 7 and Johanna Bendell 8 1 Texas Oncology, Tyler, TX; 2 Mary Crowley Cancer Research Center, Dallas, TX; 3 Suburban Hem/Onc, Lawrenceville, GA; 4 Oncology Consultants, Houston, TX; 5 Kalamazoo Hem/Onc, Kalamazoo, MI; 6 Northwest GA Oncology, Marietta, GA; 7 Keryx Biopharmaceuticals, NY, NY; 8 Sarah Cannon Research Institute, Nashville, TN PRIMARY OBJECTIVE To compare the time to progression (TTP) of patients treated with P-CAP vs. CAP as 2 nd or 3 rd line treatment for mCRC SECONDARY OBJECTIVES To further evaluate the safety of P-CAP vs. CAP To compare the overall response rate (ORR = CR + PR) and overall survival (OS) of patients treated with P-CAP vs. CAP Nearly 40% of colorectal tumors have alterations in the PI3 kinase/Akt pathway, including activating mutations in p110  or loss of PTEN 1,2,3 Perifosine is a novel oral signal transduction modulator with multiple effects including Akt and NF-  B inhibition A potential mechanism of resistance to 5-FU is upregulation of NF-  B 4 Capecitabine (Xeloda ® ) has demonstrated activity in the treatment of metastatic colorectal cancer (mCRC), though single agent efficacy is limited in patients who previously progressed on 5-fluorouracil (5-FU) therapy 5 A phase I trial has shown perifosine 50 mg QD safely combines with capecitabine 825 mg/m 2 BID d 1 – 14 every 21 days, and has demonstrated preliminary efficacy signals in patients with mCRC Based on the phase I results, an exploratory ph II randomized double-blind, placebo controlled study was initiated in patients with 2 nd or 3 rd line mCRC evaluating perifosine + capecitabine (P-CAP) vs. placebo + capecitabine (CAP) Efficacy results presented at ASCO GI 2010 showed an improvement in ORR (20% vs. 7%) and with a statistically significant improvement in time-to-progression (TTP) and in overall survival (OS) for all evaluable and 5-FU refractory patients treated with P-CAP vs. CAP 6 We now report the final results of this trial, as well as final results for the subset of patients with 5-FU refractory mCRC PATIENT POPULATION Patients with 2 nd or 3 rd line mCRC No previous treatment with capecitabine in the metastatic setting Previous treatment with 5-FU or a 5-FU based regimen Plts > 100K ANC > 1.5 HCT > 28% Creatinine < 2.5 mg/dl ECOG PS: patients evaluable for response (3 patients on CAP not evaluable; 2 due to toxicity (days 14, 46), 1 due to new malignancy on day 6) In this randomized phase II trial, perifosine + capecitabine (P-CAP) demonstrates an improvement in TTP and OS compared to placebo + capecitabine (CAP) in patients with 2 nd or 3 rd line mCRC. ORR was also improved for P-CAP over CAP. The improvements in TTP and OS with P-CAP compared to CAP are also seen in patients with 5-FU refractory disease. One patient with 5-FU refractory disease had a PR on P-CAP. P-CAP was well tolerated compared to CAP alone. A phase I study to evaluate the combination of perifosine + capecitabine using a higher dose of capecitabine at 1000 mg/m 2 PO BID days 1 – 14 is complete. No DLT’s were observed and the combination was well tolerated (ASCO 2010 Abstract 51462). PK of perifosine and capecitabine are being examined. Given the improvement in efficacy seen in this randomized phase II trial of P-CAP compared to CAP in 5- FU refractory patients, a randomized phase III study comparing P-CAP to CAP in patients with refractory mCRC is now open (X-PECT Trial). ASSESSMENT RECIST 1.0 criteria for response rate and NCI CTCAE v3.0 for toxicity assessment ADVERSE EVENTS (n = 38) ALL EVALUABLE (n = 35) CONCLUSIONS The Investigators wish to thank the Research Nurses, Staff, and especially the Patients and Families for their participation in this Study Kaplan-Meier method was used to calculate TTP and OS Groupn CR n (%) PR n (%) Duration of Response SD > 12 wks n (%) CR + PR + SD > 12 wks* n (%) PD < 12 wks n (%) P-CAP201 (5%)3 (15%) CR: 36 months 11 (55%)15 (75%)5 (25%) PR: 21, 19, 11 months CAP1501 (7%) PR: 7 months 5 (33%)6 (40%)9 (60%) Grade 3 & 4 Adverse Events: > 10% Adverse EventP-CAP (n=20)CAP (n=18) Hand and Foot6 (30%)0% Anemia3 (15%)0% Abdominal Pain1 (5%)2 (11%) Fatigue0%2 (11%) Bowel Obstruction0%2 (11%) *Survival calculated from date of randomization until date of death from any cause, whether or not additional therapies were received after removal from treatment Most Common Grade 1 & 2 Adverse Events Adverse Event P-CAP (20 pts) n (%) CAP (18 pts) n (%) Diarrhea15 (75%)5 (28%) Fatigue10 (50%)6 (33%) Nausea9 (45%)5 (28%) Musculoskeletal Pain6 (30%)3 (17%) Hand and Foot5 (25%)4 (22%) Mucositis5 (25%)1 (6%) Anorexia5 (25%)2 (11%) Anemia5 (25%)3 (17%) Prior Rx P-CAP (n=20) CAP (n=18) All Patients (n=38) FOLFIRI18 (90%)16 (89%)34 (89%) FOLFOX15 (75%)13 (72%)28 (74%) FOLFIRI & FOLFOX 13 (65%)12 (67%)25 (66%) Bevacizumab15 (75%)15 (83%)30 (79%) EGFR Antibody 9 (45%)10 (56%)19 (50%) Demographic P-CAP (n=20) CAP (n=18) All Patients (n=38) Median Age65 ( )66 ( )65 (32 – 83) Male / Female14 / 69 / 923 / 15 Median Prior Rx2 (1 – 4)2 (2 – 5)2 (1 – 5) ECOG PS 0 / 16 / 145 / 1311 / 27 Refractory to Prior 5-FU 14 (70%)13 (72%)27 (71%) Groupn PR n (%) Duration of Response SD > 12 wks n (%) CR + PR + SD > 12 wks n (%) PD < 12 wks n (%) P-CAP141 (7%)19 months8 (57%)9 (64%) p= (36%) CAP110-3 (27%) 8 (73%) 5-FU REFRACTORY (n = 25) RESULTS: OVERALL SURVIVAL* (OS) ALL EVALUABLE PATIENTS 5-FU REFRACTORY PATIENTS 1.Brugge, J., M.C. Hung, and G.B. Mills, A new mutational AKTivation in the PI3K pathway. Cancer Cell, (2): p Rychahou, P.G., et al., Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. PNAS, (51): p Sawai, H., et al., Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol, : p Voboril, R., et al., Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res, (2): p Lee, J.J., et al., Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol, (7): p Bendell, J., et al., Randomized Phase II Study of Perifosine in Combination with Capecitabine (P-CAP) vs. Placebo Plus Capecitabine (CAP) in Patients with Second or Third Line Metastatic Colon Cancer. Abstract 447, ASCO 2010 Gastrointestinal Cancers Symposium Median time to Grade 3/4 Hand & Foot Syndrome for P-CAP: 19 weeks (range 3 – 49 weeks) RESULTS: TIME TO PROGRESSION (TTP) REFERENCES RESULTS: OVERALL RESPONSE RATE (ORR) RESULTS: SAFETY PATIENT CHARACTERISTICSINTRODUCTION OBJECTIVES TREATMENT REGIMEN Median TTP: P-CAP: 28 weeks [95% CI (12, 48)] Median TTP: CAP: 11 weeks [95% CI (9, 15.9)] p-value = Hazard ratio: (0.127, 0.636) Median TTP: P-CAP: 18 weeks [95% CI (12, 36)] Median TTP: CAP: 10 weeks [95% CI (6.6, 11)] p-value = Hazard ratio: (0.066, 0.521) *p=0.036 ALL EVALUABLE PATIENTS 5-FU REFRACTORY PATIENTS Median OS: P-CAP: 15.1 mos [95% CI (7.3, 22.3)] Median OS: CAP: 6.6 mos [95% CI (4.7, 11.7)] p-value = Hazard ratio: (0.122, 0.802) Median OS: P-CAP: 17.7 mos [95% CI (8.5, 24.6)] Median OS: CAP: 10.9 mos [95% CI (5, 16.9)] p-value = Hazard ratio: (0.193, 0.868)